Temporary cost increase from accelerated validation of new active pharmaceutical ingredients
A theme in which costs temporarily increase following the acceleration of validation for new active pharmaceutical ingredient products, putting pressure on operating profit in the chemicals-related business.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.